Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR AND LAMIVUDINE versus ABACAVIR DOLUTEGRAVIR LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR AND LAMIVUDINE versus ABACAVIR DOLUTEGRAVIR LAMIVUDINE.
ABACAVIR AND LAMIVUDINE vs ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, it is phosphorylated to carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and by incorporating into viral DNA, causing chain termination. Lamivudine is a synthetic nucleoside analogue. Intracellularly, it is phosphorylated to lamivudine triphosphate, which inhibits HIV-1 RT via DNA chain termination after incorporation into viral DNA. Both drugs are nucleoside reverse transcriptase inhibitors (NRTIs).
Abacavir is a carbocyclic synthetic nucleoside analog guanosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase. Dolutegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks viral integration into host DNA. Lamivudine is a synthetic nucleoside analog cytosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase.
One tablet (600 mg abacavir/300 mg lamivudine) orally once daily.
One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) orally once daily.
None Documented
None Documented
Abacavir: ~1.5 h; Lamivudine: 5–7 h in adults, prolonged to ~9 h in children. Clinically, twice-daily dosing maintains therapeutic concentrations.
Abacavir: 1.5 hr (terminal half-life ~1.5 hr, but intracellular carbovir-TP half-life ~12-20 hr supports once-daily dosing). Dolutegravir: ~14 hr (terminal half-life, clinical context: once-daily dosing due to long intracellular half-life and high potency). Lamivudine: 5-7 hr (terminal half-life, intracellular half-life of lamivudine-TP ~18-22 hr supports once-daily dosing).
Abacavir: 83% renal (primarily as metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Lamivudine: ~70% renal as unchanged drug via active tubular secretion.
Abacavir: 83% renal (primarily as metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: 64% fecal (unchanged), 32% renal (minor as metabolites via UGT1A1 and CYP3A4). Lamivudine: >70% renal (unchanged via organic cation transport).
Category A/B
Category A/B
NRTI
NRTI